Post-earnings recap
Reported
Tue, Nov 6, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Biocryst Pharmaceuticals reported a wider-than-expected loss in EPS, which contributed to a 2.02% decline in stock price following the announcement. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance. Overall, the report reflects ongoing challenges that could impact investor confidence.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.28 | N/A | -16.26% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current market conditions. They highlighted ongoing efforts to address operational challenges.
Management did not provide specific revenue figures for the quarter.
The company acknowledged challenges in meeting earnings expectations.